Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme.
G GiovannoniP A BrexD DhirajJ FullartonM FreddiBarry S Rodgers-GrayKlaus SchmiererPublished in: Multiple sclerosis journal - experimental, translational and clinical (2019)
GA had a beneficial effect on long-term disability and was a cost-effective treatment for RRMS.